Biovectra, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. have announced a collaboration that grants Biovectra access to Revolution Biomanufacturing’s proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translational efficiency. This partnership provides a fully integrated pathway from mRNA sequence design through sterile drug product manufacturing, supporting customers with end-to-end development and ...